Alpha interferon treatment in myasthenia gravis: Effects on natural killer cell activity

Journal of Neuroimmunology

Volumn 82, Issue 2, 1998, Pages 109-115

  Bolay, Hayrunnisa ^a   Karabudak, Rana ^a   Aybay, Cemalettin ^b   Candemir, Hande ^a   Varli, Kubilay ^a   Imir, Turgut ^b   Kansu, Emin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

CD4 8; CD56; Interferon ; Myasthenia gravis; NK activity

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CHOLINERGIC RECEPTOR ANTIBODY; HLA DR ANTIGEN; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ARTICLE; AUTOIMMUNITY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ELECTROMYOGRAM; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MALE; MYASTHENIA GRAVIS; NATURAL KILLER CELL; NAUSEA; PHENOTYPE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIBODIES; BETA 2-MICROGLOBULIN; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC;

EID: 0031893082     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00146-X     Document Type: Article

References (38)

1. Abbott R.J., Holder D., Currie S. False positive anti-acetylcholine receptor antibodies in motor neuron disease. Lancet. 1(8486):1986;906-907.
2. Abruzzo L.V., Rowley D.A. Homeostasis of the antibody response: Immunoregulation by NK cells. Science. 222:1983;581-585.
3. Anlar B., Kuruolu R., Varlý K., Renda Y. Acetylcholine receptor antibodies and single fibre EMG in first degree relatives of children with myasthenia gravis. Neuropediatrics. 26:1995;335-336.
4. Aoki T., Drachman D.B., Asher D.M.et al. Attempts to implicate viruses in myasthenia gravis. Neurology. 35:1985;1381-1384.
5. Arai S., Yamamato H., Itoh K., Kumagai K. Suppressive effect of human natural killer cells on pokeweed mitogen-induced B-cell differentiation. J. Immunol. 131(2):1983;651-657.
6. Aybay C., Ýmir T., Okur H. The effect of omeprazole on human natural killer activity. Gen. Pharmacol. 26:1995;1413-1418.
7. Batocchi A.P., Evoli A., Servidei S., Palmisani M.T., Apollo F., Tonalli P. Myasthenia gravis during interferon alfa therapy. Neurology. 45:1995;382-383.
8. Biron C.A., Byron K.S., Sullivan J.L. Severe herpes virus infections in a adolescent without natural killer cells. N. Eng. J. Med. 320:1989;1731.
9. Boyum A. Isolation of lymphocytes, granulocytes and macrophages. Scand. J. Immunol. 5 (Suppl.):1976;9-15.
10. Bukowski J.F., Warner J.F., Dennert G.et al. Adoptive transfer studies demontrating the antiviral effect of natural killer cells in vivo. J. Exp. Med. 161:1985;40.
11. Burn D.J., Ball J., Lees A.J., Behan P.O., Morgan-Hughes J.A. A case of progressive encephalomyelitis with rigidity and positive antiglutamic acid dehydrogenase antibodies. J. Neurol. Neurosurg. Psychiatr. 54:1991;449-451.
12. Cavda R., Tumbarello M., Ortona L.et al. Inhibition of human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. Cell Immunol. 115:1988;57-65.
13. Cern A., Chisary F.V. Immunological aspects of HCV infection. Intervirology. 37:1994;119-125.
14. Cueva J., Löshl D., Andre P., Warter J.M., Poindron P. Administration of interferon suppresses clinical and electromyographic signs of MG experimentally transmitted from man to rats. C. R. Acad. Sci. III. 301(4):1985;125-130.
15. Garcia-Penarrubia, P., 1992. Natural killer cells in bacterial infection. In: Lewis, C.E., McGee, J.O. (Eds.), The Natural Killer Cell. Oxford University Press, New York, pp. 67-105.
16. Kott E., Hahn T., Huberman M., Levin S., Schattner A. Interferon system and natural killer cell activity in myasthenia gravis. Quart. J. Med. 281:1990;951-960.
17. Lefvert A.K., Björkholm M. Antibodies against the acetylcholine receptor in hematologic disorders: Implications for the development of myasthenia gravis after bone marrow grafting. N. Eng. J. Med. 317(3):1987;170.
18. Lewis, J.A., 1992. Effects of interferons on mitochondria: Regulation of mitochondrial gene expression. In: Susman M. (Ed.), Interferon: Principles and Medical Applications. The University of Texas Medical Branch at Galveston, TX, pp. 251-260.
19. Mantegazza R., Antozzi C., Peluchetti D., Sghirlanzoni A., Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J. Neurol. 235:1988;449-453.
20. Mase G., Zorzon M., Biasutti E., Vitrani B., Cazzato G. Development of myasthenia gravis during interferon-α treatment for anti-HCV positive chronic hepatitis. J. Neurol. Neurosurg. Psychiatr. 60:1996;348-349.
21. Masters C.L., Dawkins R.L., Zilko P.J., Simpson J.A., Leedman R.S., Lindstom J. Penicillamine associated myasthenia gravis, anti-acetylcholine receptor and anti-striatal antibodies. Am. J. Med. 63:1977;689-694.
22. Miller A.E., Hudson J., Tindall S.A. Immune regulation in myasthenia gravis: Evidence for an increased suppressor T-cell population. Ann. Neurol. 12:1982;341-347.
23. Morio T., Monoyama S., Yata J. Suppression of in vitro immunglobulin synthesis by CD16(leu11a)+CD56(NHK1 leu19)+non T cell lineage NK cells: Lack of suppression of cells from immundeficient patients. Clin. Exp. Immunol. 78:1989;159-165.
24. O'Shea, J., Ortaldo, J.R., 1992. The biology of natural killer cells: Insights into the molecular basis of function. In: Lewis, C.E., McGee, J.O. (Eds.), The Natural Killer Cell. Oxford University Press, New York, pp. 1-40.
25. Osserman, K.L., 1958. Clinical aspects. In: Myasthenia gravis. Grunex Stratton, New York, pp. 66-89.
26. Qu Z.P., Yu L.Y., Lu C.Z., Quiado J., Lin Y.X., Hong Z. A preliminary observation on auto-cholinergic synapse dysfunction in patients with different types of epilepsy. Jpn. J. Psychiatr. Neurol. 46(2):1992;401-403.
27. Perez A., Perella M., Pastor A., Cano M., Escudero J. Myasthenia gravis induced by alpha interferon therapy. Am. J. Hematol. 49(4):1995;365-366.
28. Piccolo C., Farangiotta D., Versino M., Alfonsi E., Lombardi M. Myasthenia gravis in a patient with chronic active hepatitis C during interferon-α treatment. J. Neurol. Neurosurg. Psychiatr. 60:1996;348.
29. Rauch H.C., Montgomery I.N., Kaplan J. Natural killer cell activity in multiple sclerosis and myasthenia gravis. Immunol. Invest. 14(5):1985;427-434.
30. Reiter Z. Interferon-A: Major regulator of natural killer cell mediated cytotoxicity. J. Interferon Res. 13:1993;247-257.
31. Robertson M.J., Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 76(12):1990;2421-2438.
32. Rönnblom L.E., Alm G.V., Öberg K.E. Autoimmunity after alpha interferon therapy for malignant carcinoid tumors. Ann. Internal. Med. 15:1991;178-183.
33. Roos G., Leanderson T., Lundgre E. Interferon induced cell cycle changes in human hematopoietic cell lines and fresh leukemic cells. Cancer Res. 44:1984;2358-2362.
34. Schattner A., Duggan B.D. Natural killer cells and the pathogenesis of systemic lupus erythematosus. Arthitis Rheum. 27:1984;1072-1073.
35. Schattner A., Rager-Zisman B. Virus induced autoimmunity. Rev. Infect. Dis. 12(2):1990;204-222.
36. Schrier R.D., Rice G.P.A., Oldstone M.B.A. Suppression of NK cell activity and T cell proliferation by fresh isolates of human CMV. J. Infect. Dis. 153:1986;1084-1091.
37. Shenoy M., Baron S., Wu B., Goluszko E., Christadoss P. IFNA treatment suppresses the development of experimental autoimmune myasthenia gravis. J. Immunol. 154:1995;6203-6208.
38. Whiteside T.L., Herberman R.B. The role of natural killer cells in human disease. Clin. Immunol. Immunopathol. 53:1989;1-29.